ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials Begun At Groups, Centers

November 30, 2007

In Brief: George Vande Woude To Wistar institute Board; Donald Pinkel To Head Pediatric Leukemia Program

October 18, 1985

Markup Completed On Senate Cancer Act Renewal; Waxman Agrees To $90 Million Centers Line Item

May 2, 1980

Schmidt’s Doubts Threaten Control Saturation Program

August 22, 1975

House, Senate Meet On Appropriations Bill Differences

October 6, 1989

In Brief: Michael Grever Named DCT Deputy Director; MSK’s Burton Lee New White House Physician

March 31, 1989